Panelists:
Nicholas Harvey, PhD
Postdoctoral Research Associate
King’s College London
Panelist
Nicholas Harvey, PhD
Nicholas Harvey, PhD, is an early career biomedical scientist with expertise in molecular genetics, bioinformatics, and statistical genetics. His research has spanned exercise genomics, mitochondrial genetics, and the molecular basis of complex traits and diseases such as skeletal muscle response to exercise and genetic predisposition to Ankylosing Spondylitis.
He completed his PhD at Bond University in 2021, where he developed novel methods for mitochondrial genome sequencing and investigated genetic mechanisms of exercise adaptation. As a postdoctoral research associate at King’s College London, he contributed to large-scale studies in musculoskeletal genetics and the COVID Symptom Study Biobank, co-authoring publications on long-COVID and genetic risk profiling.
He has an H-index of 11 with over 700 citations and continues to collaborate internationally on projects at the intersection of genomics, bioinformatics, and human health.
- Time:
Ankylosing Spondylitis (AS) is a debilitating, immune-mediated disease which causes inflammation of the joints between the vertebrae, leading to stiffness, pain, and eventually fusion of the spine. The underpinnings of AS are highly complex and span genetic, environmental, and immunologic factors. Insights from proteomic analysis helps with mapping risk factors and identifying potential therapeutic targets.
In this GEN webinar, our expert speaker, Nicholas Harvey, PhD, will present findings from the largest genome-wide association study (GWAS) meta-analysis of AS to date, integrating data across diverse ancestries (e.g. European, East Asian, Turkish, and Iranian) and multiple omic layers, including the transcriptome, proteome, Mendelian randomization, and microbiome. During the webinar, you will gain new insights into AS pathogenesis, therapeutic challenges, and novel avenues for precision medicine.
Key takeaways:
- The identification of novel AS loci and signals, including 27 new genome-wide significant loci and 86 independent non-MHC associations
- The connection between AS risk and secretor status in the gut microbiome
- The impact of longer leukocyte telomeres on AS susceptibility
- The role of cytokine biology in therapy efficacy
- How to prioritize genes by applying fine-mapping to highlight causal variants
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post Unraveling Ankylosing Spondylitis: Integrating Proteomics with Global Genetic Meta-Analysis appeared first on GEN – Genetic Engineering and Biotechnology News.
